Trump Announces Deal for Regeneron’s Drug Pricing
WASHINGTON—President Donald Trump has revealed a new agreement that will implement most-favored-nation pricing for Regeneron’s latest medication within state Medicaid systems. This marks the 17th such deal he has established with a major pharmaceutical company since earlier this fall.
A fact sheet from the White House outlines that this agreement ensures that other nations won’t “exploit U.S. innovation through price controls,” by offering the MFN price for every innovative drug that Regeneron releases.
The arrangement also indicates that Regeneron must bring back any increase in foreign earnings from existing products, leveraging the President’s strong America First trade policy, all for the advantage of American patients, as stated by the White House.
According to the administration, the cost of Regeneron’s cholesterol medication, Praluent, will drop from $537 to $225 when purchased via the TrumpRx website.
During an announcement in the Oval Office, President Trump praised the deal alongside Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, other Cabinet members, and executives from Regeneron.
“Today, I’m thrilled to share that Regeneron, one of the most reputable pharmaceutical firms globally, has consented to offer its drugs at significantly reduced most-favored-nation prices,” Trump remarked.
Following the initial agreement with Pfizer disclosed on September 30, Trump announced deals with several other companies, including AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, and others.
Trump emphasized that this news means 17 of the world’s major pharmaceutical companies, which account for 80% of the branded drug market, have committed to providing their medications to Americans at lower prices than those found elsewhere.
“This will lead to the most significant drop in prescription drug costs in U.S. history. It feels like it should be leading the news, but it probably won’t be,” he added, expressing a sense of irony. “Still, the public gets it, and that’s likely why we’re here in the Oval Office,” he concluded.
